Literature DB >> 32041716

Synergistic Interactions of Indole-2-Carboxamides and β-Lactam Antibiotics against Mycobacterium abscessus.

Clément Raynaud1, Wassim Daher1, Françoise Roquet-Banères1, Matt D Johansen1, Jozef Stec2, Oluseye K Onajole3, Diane Ordway4, Alan P Kozikowski5, Laurent Kremer6,7.   

Abstract

New drugs or therapeutic combinations are urgently needed against Mycobacterium abscessus Previously, we demonstrated the potent activity of indole-2-carboxamides 6 and 12 against M. abscessus We show here that these compounds act synergistically with imipenem and cefoxitin in vitro and increase the bactericidal activity of the β-lactams against M. abscessus In addition, compound 12 also displays synergism with imipenem and cefoxitin within infected macrophages. The clinical potential of these new drug combinations requires further evaluation.
Copyright © 2020 American Society for Microbiology.

Entities:  

Keywords:  MmpL3; Mycobacterium abscessus; drug synergism; indole-2-carboxamide; macrophage; therapeutic activity; β-lactam

Mesh：

Substances：

Year:  2020        PMID： 32041716      PMCID： PMC7179587          DOI： 10.1128/AAC.02548-19

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  25 in total

1.  Synergy, antagonism, and what the chequerboard puts between them.

Authors:  F C Odds
Journal:  J Antimicrob Chemother       Date:  2003-06-12       Impact factor: 5.790

2.  Indole-2-carboxamide-based MmpL3 Inhibitors Show Exceptional Antitubercular Activity in an Animal Model of Tuberculosis Infection.

Authors:  Jozef Stec; Oluseye K Onajole; Shichun Lun; Haidan Guo; Benjamin Merenbloom; Giulio Vistoli; William R Bishai; Alan P Kozikowski
Journal:  J Med Chem       Date:  2016-06-22       Impact factor: 7.446

3.  M ycobacterium abscessus pulmonary disease: individual patient data meta-analysis.

Authors:  Nakwon Kwak; Margareth Pretti Dalcolmo; Charles L Daley; Geoffrey Eather; Regina Gayoso; Naoki Hasegawa; Byung Woo Jhun; Won-Jung Koh; Ho Namkoong; Jimyung Park; Rachel Thomson; Jakko van Ingen; Sanne M H Zweijpfenning; Jae-Joon Yim
Journal:  Eur Respir J       Date:  2019-07-11       Impact factor: 16.671

4.  In vitro evaluation of a new drug combination against clinical isolates belonging to the Mycobacterium abscessus complex.

Authors:  S Singh; N Bouzinbi; V Chaturvedi; S Godreuil; L Kremer
Journal:  Clin Microbiol Infect       Date:  2014-10-03       Impact factor: 8.067

5.  Antimicrobial resistance in Mycobacterium abscessus complex isolated from patients with skin and soft tissue infections at a tertiary teaching hospital in Taiwan.

Authors:  Ming-Chun Lee; Pei-Lun Sun; Tsu-Lan Wu; Li-Hsin Wang; Chih-Hsun Yang; Wen-Hung Chung; An-Jing Kuo; Tsui-Ping Liu; Jang-Jih Lu; Cheng-Hsun Chiu; Hsin-Chih Lai; Nan-Yu Chen; Jeng-How Yang; Ting-Shu Wu
Journal:  J Antimicrob Chemother       Date:  2017-10-01       Impact factor: 5.790

6.  In Vitro Activity of the New β-Lactamase Inhibitors Relebactam and Vaborbactam in Combination with β-Lactams against Mycobacterium abscessus Complex Clinical Isolates.

Authors:  Amit Kaushik; Nicole C Ammerman; Jin Lee; Olumide Martins; Barry N Kreiswirth; Gyanu Lamichhane; Nicole M Parrish; Eric L Nuermberger
Journal:  Antimicrob Agents Chemother       Date:  2019-02-26       Impact factor: 5.191

7.  Indole-2-Carboxamides Are Active against Mycobacterium abscessus in a Mouse Model of Acute Infection.

Authors:  Amit N Pandya; Pavan K Prathipati; Pooja Hegde; Wei Li; Kyle F Graham; Subhra Mandal; Kristen M Drescher; Christopher J Destache; Diane Ordway; Mary Jackson; E Jeffrey North
Journal:  Antimicrob Agents Chemother       Date:  2019-02-26       Impact factor: 5.191

8.  In vitro efficacy of imipenem in combination with six antimicrobial agents against Mycobacterium abscessus.

Authors:  Tomomitsu Miyasaka; Hiroyuki Kunishima; Mayumi Komatsu; Kiyoko Tamai; Kotaro Mitsutake; Keiji Kanemitsu; Yoshiharu Ohisa; Hideji Yanagisawa; Mitsuo Kaku
Journal:  Int J Antimicrob Agents       Date:  2007-07-09       Impact factor: 5.283

9.  In Vitro and Intracellular Activity of Imipenem Combined with Rifabutin and Avibactam against Mycobacterium abscessus.

Authors:  Eva Le Run; Michel Arthur; Jean-Luc Mainardi
Journal:  Antimicrob Agents Chemother       Date:  2018-07-27       Impact factor: 5.191

10.  US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis: executive summary.

Authors:  R Andres Floto; Kenneth N Olivier; Lisa Saiman; Charles L Daley; Jean-Louis Herrmann; Jerry A Nick; Peadar G Noone; Diana Bilton; Paul Corris; Ronald L Gibson; Sarah E Hempstead; Karsten Koetz; Kathryn A Sabadosa; Isabelle Sermet-Gaudelus; Alan R Smyth; Jakko van Ingen; Richard J Wallace; Kevin L Winthrop; Bruce C Marshall; Charles S Haworth
Journal:  Thorax       Date:  2016-01       Impact factor: 9.139
View more
  3 in total

1.  In Vitro Activity of Bedaquiline and Imipenem against Actively Growing, Nutrient-Starved, and Intracellular Mycobacterium abscessus.

Authors:  Olumide Martins; Jin Lee; Amit Kaushik; Nicole C Ammerman; Kelly E Dooley; Eric L Nuermberger
Journal:  Antimicrob Agents Chemother       Date:  2021-09-13       Impact factor: 5.191

Review 2.  Pipeline of anti-Mycobacterium abscessus small molecules: Repurposable drugs and promising novel chemical entities.

Authors:  Anna Egorova; Mary Jackson; Victor Gavrilyuk; Vadim Makarov
Journal:  Med Res Rev       Date:  2021-03-01       Impact factor: 12.388

Review 3.  Alternative and Experimental Therapies of Mycobacterium abscessus Infections.

Authors:  Michal Meir; Daniel Barkan
Journal:  Int J Mol Sci       Date:  2020-09-16       Impact factor: 5.923
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.